Skip to main content

RGD-Conjugated PLA-PLL Nanoparticles Targeting to Bacp-37 Breast Cancer Xenografts In Vivo

Buy Article:

$113.00 plus tax (Refund Policy)


Targeted delivery carriers are receiving considerable attention, the development of a more precise targeted delivery carrier is critical for the advancement of cancer chemotherapy. In this study, we evaluated the effects of RGD-conjugated poly (lactic acid-co-lysine)-(Arginine-Glycine-Aspartic) nanoparticles (PLA-PLL-RGD NPs) on targeted delivery to Bacp-37 breast cancer bearing mice. PLA-PLL-RGD NPs were prepared by using the emulsion-solvent evaporation method. A subsequent MTT assay indicated that the NPs were non-toxic and had good biocompatibility. In vitro, the results of Confocal Laser Scanning Microscope (CLSM) and FAC Scan flow cytometry (FACS) indicated that the PLA-PLL-RGD NPs can bind more significantly to human umbilical vein endothelial cells, compared to PLA-PLL NPs. In vivo, the results of target imaging and biodistribution showed that PLA-PLL-RGD can significantly target to tumor of Bacp-37 breast cancer bearing mice. These results demonstrated that PLA-PLL-RGD NPs can effectively enhance targeted efficiency in vivo, and have the potential to be used as targeted delivery carrier.


Document Type: Research Article


Publication date: December 1, 2011

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more